GlobeNewswire

Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025
04/12/2025
Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 Atavistik Bio’s [...]
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding [...]
Microbix Announces Initiation of Normal Course Issuer Bid
04/12/2025
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ) (“Microbix” or the “Company”), a [...]
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
04/12/2025
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio , a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea , a leading global contract research [...]
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
04/12/2025
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the [...]
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
04/12/2025
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global [...]
Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
04/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced [...]
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
04/12/2025
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the [...]
Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting
04/12/2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune ® , Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination [...]
Diagonal Therapeutics to Present Insights from HHT IMPACT, a Natural History Study Initiated in Partnership with Cure HHT, at ASH 2025
04/12/2025
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform design of [...]
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
04/12/2025
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file [...]
ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer
04/12/2025
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark [...]
Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/12/2025
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in patients with advanced [...]
Beghou Adds New Partners to Advance Integrated, Experience-Driven Commercialization in Life Sciences
04/12/2025
New additions enable clients to better connect pre-launch strategy through in-market execution—aligning intelligence and teams to drive effective launches and more cohesive customer engagement EVANSTON, Ill., Dec. 04, [...]
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
04/12/2025
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11: [...]
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
04/12/2025
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes [...]
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
04/12/2025
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological, molecular, and anatomical evidence MIAMI, [...]
Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
04/12/2025
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification – – AJ1-11095 [...]
Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE
04/12/2025
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum